# Ifosfamide

## Indication
Rhabdomyosarcoma primary site  
**ICD11 code:** 2C25.Z

## INN
Ifosfamide

## Medicine type
Chemical agent

## List type
Complementary

## Formulations
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

## EML status history
First added in 2009 (TRS 958)  
Changed in 2015 (TRS 994)

## Sex
All

## Age
Also recommended for children

## Therapeutic alternatives
The recommendation is for this specific medicine

## Patent information
Patents have expired in most jurisdictions  
Read more about patents.

## Tags
Cancer

## Wikipedia
[Ifosfamide](https://en.wikipedia.org/wiki/Ifosfamide)

## DrugBank
[Ifosfamide](https://www.drugbank.ca/drugs/DB00638)

---

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. Additionally, ifosfamide was included on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.

[Expert Committee report](https://www.who.int/healthsystems/publications/essentialmedicines-trs994/en/)

---

---

---